Compare SELX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SELX | NEUP |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | Taiwan | United States |
| Employees | N/A | 8 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 24.9M |
| IPO Year | 2023 | N/A |
| Metric | SELX | NEUP |
|---|---|---|
| Price | $0.30 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 11.4K | ★ 59.5K |
| Earning Date | 05-08-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $3.65 |
| 52 Week High | $1.85 | $21.31 |
| Indicator | SELX | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 25.32 | 37.85 |
| Support Level | N/A | $4.01 |
| Resistance Level | $1.04 | $4.56 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 7.34 | 12.22 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.